Pharmacogenetics and inflammatory bowel disease: progress and prospects

Inflamm Bowel Dis. 2004 Mar;10(2):148-58. doi: 10.1097/00054725-200403000-00014.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenal Cortex Hormones / genetics
  • Adrenal Cortex Hormones / therapeutic use
  • Antibodies, Monoclonal / genetics
  • Antibodies, Monoclonal / therapeutic use
  • Azathioprine / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Forecasting
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / genetics*
  • Infliximab
  • Male
  • Mercaptopurine / therapeutic use
  • Methotrexate / therapeutic use
  • Pharmacogenetics / standards
  • Pharmacogenetics / trends*
  • Prognosis
  • Risk Assessment
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Infliximab
  • Mercaptopurine
  • Azathioprine
  • Methotrexate